SHED reduced mechanical sensitivity, inflammatory cell infiltration, and TRPV1 expressions, with effects lasting 8 weeks. Results support SHED as a potential therapy for trigeminal neuralgia. The gene discussed is TRPV1; the disease is trigeminal neuralgia.